AdAlta CEO Sam Cobb met with Morgans Senior Analyst, Scott Power, in August 2018 to provide an introduction to AdAlta, an update on the progress of improved lead candidate, AD-214 and some background on Idiopathic Pulmonary Fibrosis, a lung condition in desperate need of new treatment options for which AdAlta is developing AD-214. The interview can be viewed below and AdAlta’s latest company presentation can be found here.
